Navigation Links
Hormone Therapy May Fight Resistant Prostate Cancer
Date:4/14/2010

Experimental treatment offers hope against cancer that returns after castration

WEDNESDAY, April 14 (HealthDay News) -- Preliminary research suggests that a new hormone treatment could be a weapon for doctors in the battle against a form of prostate cancer that's resistant to surgical removal of the testicles.

Only two of the three phases of research required for new drug treatments have been completed, however. At this point, it's not clear whether the treatment will go on to receive federal approval.

The hormone treatment, called MDV3100, is being tested as a treatment for a disease known as castration-resistant prostate cancer, according to a report on the research, published online April 14 in The Lancet.

Prostate tumors need testosterone to grow. One treatment involves castration, possibly with additional drug treatment, to combat the body's processing of testosterone.

Though the treatment kills some cancer cells, others remain alive but dormant, the researchers explained in a news release from the journal. And these cells can re-grow and survive without as much testosterone, thus becoming castration-resistant, they said.

For their study, Dr. Howard Scher of Memorial Sloan-Kettering Cancer Center in New York City and his colleagues tested the MDV3100 hormone treatment in 140 men in the United States with castration-resistant prostate cancer. The researchers gave varying doses, from 30 to 600 milligrams a day, to the men to find the maximum tolerable dose, which they determined to be 240 milligrams.

"We recorded encouraging anti-tumor activity with MDV3100 in patients with castration-resistant prostate cancer," both before and after chemotherapy, the researchers wrote in their report.

The researchers have begun a third phase of testing in which they will compare the hormone treatment to a placebo to see if it helps men with advanced prostate cancer live longer.

More information

For more about prostate cancer, visit the U.S. National Cancer Institute.



-- Randy Dotinga



SOURCE: The Lancet, news release, April 14, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Hormones Tied to Diabetes Might Also Influence Fertility
2. Anti-aging hormones: Little or no benefit and the risks are high
3. Demonstrated in vivo the transfer of maternal thyroid hormones to the fetus
4. Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women
5. Promising hormone may help reduce malnutrition in gastric cancer patients
6. Hormone Replacement Might Relieve Arthritis
7. Hormone replacement in joint fluid has potential regenerative effect
8. Another perk of painkillers? Decreased hormone levels may reduce cancer risk
9. Metagenics Launches Estrovera™, an All-Natural, Clinically Demonstrated Alternative to Hormone Therapy for Relief of Hot Flashes and Other Menopausal Symptoms*
10. Thyroid hormone analogue for treating high cholesterol
11. Thyroid Hormone Analogue for Treating High Cholesterol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... , ... May 24, 2017 , ... ... of ExtraHop to its solutions portfolio. ExtraHop delivers an analytics-first approach, layered with ... every IT system, from the datacenter to the cloud to the edge. Through ...
(Date:5/24/2017)... ... 24, 2017 , ... The CFOs included on this list ... in the nation and help their organizations navigate the challenges in healthcare today. ... in developing successful hospital and health system strategy. , Becker's Hospital Review has ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International (MDLand), a ... today that its iClinic V12.2 solution has achieved approval from National Center for ... PCMH 2017 standards which emphasize team-based care with a significant focus on the ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, May ... since 2009, according to a Workers Compensation Research Institute (WCRI) study, a contrast ... North Carolina System: CompScope™ Benchmarks, 17th Edition looks at indemnity and medical ...
(Date:5/23/2017)... ... 2017 , ... London, May 23, 2017: Walter Schindler, the Founder and Managing ... Guest Speaker and Contributor to a weeklong series of classes, meetings, field trips and ... , Walter Schindler and SAIL Capital have received an increasing number ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/18/2017)... -- Bayer announced today that the latest research from across ... 53 rd Annual Meeting of the American Society ... Chicago . The ... and thyroid cancers, as well as lymphomas, and includes ... of copanlisib in patients with relapsed or refractory follicular ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
Breaking Medicine Technology: